3Schwartzbaum JA, Fisher JL, Aldape KD, et al. Epidemiology and molecular pathology of glioma [J ] 1- Nat Clin Pract Neurol, 2006, 2(9) : 494-503.
4Guo YF, Wang XB, Tian XY, et al. Tumor-derived hepatocyte growth factor is associated with poor prognosis of patients with glio- ma and influences the chemosensitivity of glioma cell line to cispl- atin in vitro [J]. World J Surg Oncol, 2012, 10(1) : 128-138.
5Weller M. Novel diagnostic and therapeutic approaches to malig- nant glioma [J]. Swiss Med Wkly, 2011, 141: w13210.
6Stupp R, Hegi ME, Gilbert MR, et al. Chemoradiotherapy in ma- lignant glioma: standard of care and future directions [ J ]. J Clin Oncol, 2007, 25(26) : 4127-4136.
7Han SJ, Zygourakis C, Lira M, et al. Immunotherapy for glioma: promises and challenges [J]. Neurosurg Clin N Am, 2012, 23 (3) : 357-370.
8Rahman M, Hob B, Kohler N, et al. The future of glioma treat- ment: stem cells, nanotechnology and personalized medicine [ J ]. Future Oncol, 2012 , 8(9) : 1149-1156.
9Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance [ J ]. Oncoene. 2012. 31 ( 15 ) : 1869-1883.
10Miller SC, Pandi-Perumal SR, melatonin in immuno-enhancem Esquifino AI, et al. The role of Potential application in cancer [J]. Int J Exp Pathol, 2006, 87(2) : 81-87.
